China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD 21.8 million) in revenue, a 9% year-on-year (YOY) decline. This decrease was primarily due to the implementation of a commercial activity optimization strategy in the second half of 2024 and a business personnel organizational efficiency plan. The company’s gross profit margin decreased from 50.7% in 2023 to 48.9% in 2024, alongside a narrowed loss of RMB 590 million (USD 81 million) this year compared to 2023.
Strategic Explorations and Progress
In 2024, JW Therapeutics began exploring the potential of Carteyva (relmacabtagene autoleucel injection) in solid tumors after achieving significant progress with the anti-CD19 autologous CAR-T cell immunotherapy in hematologic malignancies. Carteyva also shows promise as a treatment for systemic lupus erythematosus.
Market Coverage Expansion
As of December 31, 2024, Carteyva has been covered by over 80 commercial insurances and 102 supplementary medical insurance plans of local governments, enhancing its accessibility and market presence.-Fineline Info & Tech
Leave a Reply